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Units of red blood cell (RBC) concentrates with rare phenotypes 
are typically not included in method validation studies for 
cryopreservation processes; rather, they are reserved for 
patients with rare blood needs. Some rare RBC phenotypes 
may demonstrate membrane abnormalities, like acanthocytosis 
as observed for RBCs with the McLeod phenotype, and are 
specifically banked for these rare attributes; however, the impact 
that rare RBC phenotypes have on post-thaw quality has not been 
well studied. To evaluate how a rare RBC phenotype is affected 
by the cryopreservation process, 4 RBC units, cryopreserved in 
1993 using manual methods, were selected for evaluation. These 
RBCs included one with the McLeod phenotype and three with 
phenotypes not known to cause significant membrane changes. 
Post-thaw, an altered deglycerolization protocol, implemented 
to reduce supernatant glycerol after cryopreservation, was 
used before processing RBCs on an automated closed system 
(ACP 215; Haemonetics, Boston, MA) to accommodate the 
use of a closed system cell processor not available when the 
RBC units were previously cryopreserved. RBC quality was 
tested at 24 hours, 7 days, and 14 days post-deglycerolization. 
Before deglycerolization, an extracted sample from the thawed 
glycerolized RBC unit was used to obtain genetic material for 
phenotype confirmation. Genotyping confirmed the McLeod 
phenotype. When comparing McLeod with non-McLeod units, 
RBCs from the McLeod donor exhibited acanthocytosis, higher 
rigidity, and lower morphology scores than RBCs from the non-
McLeod units post-deglycerolization. Hemolysis, however, was 
comparable across all 4 units, meeting regulatory standards. 
Therefore, McLeod RBCs can withstand cryopreservation, 
suggesting that units from these donors, glycerolized using 
older methods, can be deglycerolized using the ACP 215 and 
stored hypothermically for 14 days. It was also determined 
that genotyping can be performed on non-leukocyte–reduced 
cryopreserved RBCs, allowing for confirmation of genetic 
profiles of donor units banked before the implementation of 
molecular methods. Immunohematology 2021;37:78–83. 
DOI:21307/immunohematology-2021-012.
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Cryopreservation of red blood cell (RBC) concentrates is 
used for long-term storage of rare phenotyped RBCs to provide 
life-saving therapies to patients. To produce these components 
in Canada, blood manufacturers must demonstrate that 
the production method they use yields RBC units that meet 
regulatory guidelines for hemolysis, hemoglobin (Hgb) content, 
and RBC recovery.1 The Canadian Blood Services (CBS) Rare 
Blood Program maintains a carefully selected inventory of 
cryopreserved RBCs with rare phenotypes, although these 
units are not represented in method validation or quality control 
data sets presently used to establish standard cryopreservation 
methods. This finding is problematic, since rare donor RBCs 
may have abnormal morphology and membrane structure that 
can affect component quality associated with the mechanical 
stresses of cryoprotectant addition/removal, freezing, thawing, 
and cell processing. Considering there is little evidence of 
the effect that rare phenotypes associated with membrane 
alterations have on deglycerolized RBC component quality, 
investigations to evaluate the downstream implications to 
patient care and cell banking practices would be useful.
An example of a rare RBC phenotype that should 
be cryogenically banked is the McLeod phenotype. This 
phenotype results from the absence of the Kx protein on the 
RBC membrane due to various missense and small to major 
nucleotide deletions of the XK gene.2,3 This information is 
important because Kx, a 10-pass transmembrane protein 
disulfide linked to the Kell glycoprotein, contributes to the 
normal structure of biconcave-shaped RBCs, and the lack 
thereof could affect the ability of the RBCs to withstand 
the stresses associated with cryopreservation.2–6 These 
membrane changes produce RBCs exhibiting various degrees 
of acanthocytosis, which can lead to compensated hemolytic 
anemia in patients with the McLeod phenotype, resulting in 
the need for transfusion and the necessity for cryopreserved 
components to meet future autologous and allogeneic use.3–5,7,8 
However, component quality post-deglycerolization for this 
phenotype has not been previously described.
In addition to the challenge of understanding how 
RBCs having rare blood phenotypes can tolerate the 
cryopreservation process, blood manufacturers are also 
faced with the implications of long-term storage of these 
components. Cryopreserved RBCs can be stored for up to 10 
years (30 years in Canada and other jurisdictions with medical 
approval), ensuring the availability of rare RBCs in acute 
clinical scenarios. However, given the pace of technological 
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change, evaluating the impact of manufacturing changes must 
be ongoing to confirm that components frozen using older 
methods are compatible with new processing equipment and 
quality is maintained. The study presented herein evaluated 
the quality of cryopreserved donor RBC units stored for more 
than 20 years, including a previously identified McLeod 
donor unit. The RBC units were originally glycerolized and 
frozen using a manual method intended for deglycerolization 
on a semi-automated cell processor (COBE 2991; Terumo 
BCT, Lakewood, CO). CBS now uses a closed-system 
automated processor (ACP 215; Haemonetics, Boston, MA) 
for glycerolization and deglycerolization of RBCs requiring 
certain adaptations to be made to process the thawed RBCs 
evaluated in this study. Furthermore, because diagnostic 
testing has also improved since this rare McLeod donor unit 
was cryopreserved, this study also aims to evaluate whether 
samples from non-leukocyte–reduced cryopreserved RBCs 




To evaluate the component quality of the McLeod donor 
RBC unit, 3 additional cryopreserved RBC units were selected 
as controls. These units lacked RBC antigen phenotypes 
associated with known membrane abnormalities and had 
been cryopreserved in the same year (1993) and at the same 
site using the same method (high-glycerol method [40%] in 
Charter Medical [Winston-Salem, NC] containers) as that for 
the McLeod donor unit.
Unit Processing
Twenty-four years after cryopreservation, each unit was 
thawed individually in a circulating 37°C water bath for up 
to 15 minutes. Before deglycerolization, the contents of the 
units were transferred to a 1-liter bag (OMAVSE6000XU; 
Macopharma, Mouvaux, France) followed by supernatant 
reduction. This reduction was performed by centrifuging the 
RBCs (HBB-6 Rotor, 2070g, ACE 2.88 × 107, 18–24°C, Sorvall 
RC 3BP+; Thermo Fisher, Langenselbold, Germany) to pack the 
cells followed by supernatant removal using a manual plasma 
extractor (4R4414; Fenwal, Lake Zurich, IL). The unit was 
sterile docked (CompoDock; Fresenius Kabi, Bad Homburg, 
Germany) to a processing set (LN235; Haemonetics), 
which was pre-loaded into the closed-system cell processor 
(Haemoentics ACP 215), and automated deglycerolization 
was initiated using two different concentrations of saline 
solutions (12% sodium chloride 4B7874Q, and 0.2% dextrose 
and 0.9% sodium chloride processing solution 4B7878; Baxter, 
Mississauga, ON, Canada). Finally, the deglycerolized RBCs 
were suspended in AS-3 (462A; Haemonetics) before storage 
in a 1–6°C refrigerator for 14 days.
Unit Sampling
Each RBC unit was sampled at five different time 
points: 10 mL immediately post-thaw; 1 mL immediately 
post-deglycerolization; and 5 mL at 1, 7, and 14 days post-
deglycerolization. Briefly, the RBC unit was mixed by gentle 
massage while inverting five times. A sampling site coupler 
(R4R1401; Fenwal) was inserted into one of the ports on 
the RBC bag. Using aseptic technique, an 18-gauge needle 
attached to a syringe was inserted through the coupler, and 
the desired sample volume was drawn slowly into the syringe. 
After removal of the needle, the sample was aliquoted dropwise 
into sample tubes for analysis.
Component Quality Testing
Immediately post-thaw and post-deglycerolization, RBCs 
were analyzed for RBC hemolysis to determine whether there 
was any noticeable damage due to the length of storage or 
processing methods. Component quality was tested at 1, 7, and 
14 days post-deglycerolization—testing for RBC hemolysis, 
supernatant potassium, Hgb content, adenosine triphosphate 
(ATP) concentration, RBC deformability, RBC indices, osmotic 
fragility, and morphology, all as previously described.9–11
Genotyping and Phenotyping
To obtain genomic material for this study, a method to 
collect samples for analysis from a thawed RBC component 
was developed. Immediately post-thaw, samples were 
prepared by centrifuging 9 mL of glycerolized RBCs at 2200g 
for 10 minutes at room temperature. The resulting supernatant 
was removed and approximately 2 mL of sample from the 
buffy coat region (cell interface) where white blood cells should 
be present was extracted. Samples were frozen at less than 
–65°C until DNA extraction could be completed, which was 
performed using a commercial kit (QIAamp DNA Blood Mini 
Kit [51104]; Qiagen, Hilden, Germany). Extracted genomic 
DNA were shipped frozen to the Diagnostic Laboratories at 
Versiti BloodCenter of Wisconsin for molecular analysis. Real-
time polymerase chain reaction (PCR)-fluorogenic 5´ nuclease 
TaqMan chemistry was used in a mass-scale nanofluidic open-
array format (Smart-Chip Real-Time PCR System; Takara 
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Bio USA, Mountain View, CA) to determine the following 
blood group antigens: M, N, S, s, U; C, E, c, e, V, Vs, hrB, hrS, 
Crawford; K, k, Kp(a/b), Js(a/b); Fy(a/b); Jk(a/b); Lu(a/b); 
Do(a/b), Hy, Jo(a); Di(a/b); Co(a/b); Cr(a); Yt(a); and Vel.12 
To confirm the McLeod phenotype, a custom comparative 
genomic hybridization array analysis was performed that 
included overlapping exon hybridization probes in the region of 
XK (Oxford Gene Technology, Tarrytown, NY). Hybridization 
was analyzed on a scanner (Innopsys, Carbonne, France) 
using software (Mapix, version 7.3.0, and CytoSure, version 
4.7.13; Oxford Gene Technology, Begbroke, UK). Healthy male 
and female genomic DNA served as normal controls.
Serology
Deglycerolized RBCs (1 mL) from the McLeod donor 
was used for serologic phenotyping using direct agglutination 
testing with monoclonal antisera (Anti-K, Ortho 13129; Ortho 
Clinical Diagnostics, Raritan, NJ) and the indirect antiglobulin 
test (IAT) with another antisera (Anti-k [Anti-Cellano], Ortho 
721030; Ortho Clinical Diagnostics). The CBS National 
Immunohematology Reference Laboratory confirmed the 
weak Kell system reactions using additional commercial 
antisera and unlicensed polyclonal donor anti-Jsb by the IAT.
Data Analysis
Descriptive statistics were calculated for the control group 
using spreadsheet software (Excel 2016; Microsoft, Redmond, 
WA). The in vitro results obtained from the McLeod unit were 
considered either increased or decreased if the result was 




Immediately post-thaw and before deglycerolization, 
hemolysis for the McLeod RBC (still in glycerol) was 5.16 
percent. RBC hemolysis was within 1 SD of the mean of the 
control group (5.94 ± 3.87% [1 SD, n = 3]), indicating that the 
McLeod donor RBC unit was not more susceptible to cellular 
damage because of mechanical stresses of glycerolization, 
freezing, and thawing than RBC units with a typical RBC 
antigen profile. At 24 hours post-deglycerolization, all units, 
including the McLeod RBC, met the Canadian Standards 
Association (CSA) standard for hemolysis (<0.8%).1 Hemolysis 
for all units tested consistently met the required standard 
after units underwent extended hypothermic storage up 
to 14 days, the maximum allowable storage time at CBS for 
deglycerolized RBCs, indicating that McLeod RBCs withstood 
the deglycerolization process and post-thaw storage in AS-3 as 
well as the control group.
The CSA requirements for hematocrit (Hct) (≤80%) and 
Hgb content (≥35 g/RBC component in 100% of units tested 
and ≥40 g/RBC component in 90% of units tested) were met 
by all study RBCs at the accepted 24-hour expiration date 
for open-system processed units.1 The McLeod RBC unit 
had an Hct of 48 percent, which was similar to the control 
group at 48 ± 0.04 percent (1 SD, n = 3). Total Hgb content 
(a dose indicating parameter) for the McLeod RBC unit was 
54.0 g/RBC component, which was also comparable to the 
56.1 ± 5.2 g/RBC component (1 SD, n = 3) achieved for the 
control group.
Osmotic fragility was represented by the mean corpuscu-
lar fragility (MCF) of the RBCs, indicating the saline 
concentration at which 50 percent RBC hemolysis is achieved. 
Although the McLeod unit appears to have had increased MCF, 
the values obtained were within the SD of the control group at 
all storage time points (Table 1). This result was also in line 
with data previously reported in the literature by Kuypers et 
al.,13 who found that non-cryopreserved McLeod RBCs had 
similar osmotic fragility to non-McLeod RBCs (although it has 
been shown that RBCs without Kx do have decreased osmotic 
water permeability). At 24 hours post-deglycerolization, the 
McLeod unit demonstrated increased ATP and supernatant 
K+, and decreased mean cell volume (MCV), which were all 
greater than 2 SDs when compared with the control group at 
that time point (Table 1). However, this observation did not 
hold true for these parameters for the additional extended 
storage at days 7 and 14 post-deglycerolization.
RBC deformability (Fig. 1) and morphology (Fig. 2) 
demonstrate distinct differences between the McLeod unit and 
the control group, likely due to the observed acanthocytosis 
in the McLeod unit. The KEI, a measure of RBC rigidity, 
was increased in the McLeod RBCs more than 2 SDs (21-
SD difference) from the control group at 24 hours post-
deglycerolization. This result maintains greater than 2-SD 
differences when compared with the controls at 14 days of 
hypothermic storage. Figure 2A demonstrates a marked 
decrease in the morphology index of the McLeod RBCs, which 
is influenced by the presence of acanthocytes shown in Figure 
2B and slightly microcytic RBCs, as indicated by decreased 
MCV.
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Phenotyping and Genotyping
Serology results for the McLeod RBCs confirmed the 
historical phenotype kept on record at CBS for that donor. 
Typically, McLeod patients’ RBCs demonstrate weak reactions 
for the common Kell blood group system antigens (k, Kpb, 
Jsb).2–5 The donor tested in this study also demonstrated weak 
phenotype reactions for k (1+), Kpb (1+), and Jsb (3+) post-
deglycerolization. In addition, RBC genotyping confirmed that 
the donor had the genes to express k, Kpb, and Jsb. Comparative 
genomic hybridization array provided genomic evidence that 
the male donor would have a McLeod phenotype, identifying 
a 4.69-Mb arr[hg19] Xp21.1p11.1(33,341,040-38,030,042) 
× 0 hemizygous deletion resulting in the complete loss of XK 
and CYBB. This donor was confirmed as having a McLeod 
phenotype, previously identified at CBS through serology and 
the presence of corresponding anti-Kx and anti-Km before the 
donation of at least 6 autologous units for cryopreservation to 
ensure supply in case of transfusion need.
Cryopreserving McLeod donor RBCs
Table 1. In vitro parameters for hypothermically stored RBC units post-deglycerolization using the ACP 215 after manual removal of 
excess glycerol before processing
Length of hypothermic storage post-deglycerolization
McLeod (n = 1) Control group (n = 3)
Parameter 1 day 7 days 14 days 1 day 7 days 14 days
RBC hemolysis (%)
Mean (SD) 0.23 0.48* 0.55 0.19 (0.02) 0.31 (0.02) 0.52 (0.10)
ATP (µmol/g Hgb) 
Mean (SD) 4.196* 2.150 1.432 3.735 (0.223) 2.617 (0.512) 1.816 (0.349)
MCF (g/L NaCl)† 
Mean (SD) 6.104 5.986 5.918 5.541 (0.688) 5.504 (0.656) 5.473 (0.653)
Supernatant K+ (µmol/L) 
Mean (SD) 5.2* 15.0 20.6 3.7 (0.5) 13.2 (1.1) 18.8 (1.6)
MCV (fL) 
Mean (SD) 85.1* 84.9 86.3 104.1 (9.3) 98.4 (8.7) 98.4 (8.4)
*Indicates when the unit of McLeod red blood cells (RBCs) is >2 standard deviations (SDs) from the control group at the same storage time point. 
†MCF = mean corpuscular fragility (derived from osmotic fragility); MCF is presented as the concentration of sodium chloride (NaCl) in which 50 percent 
hemolysis is calculated to be achieved.
ATP = adenosine triphosphate; Hgb = hemoglobin; K+ = potassium; MCV = mean cell volume.
Fig. 1 Red blood cell (RBC) deformability represented by two index 
parameters: EIMax, the maximum elongation of RBCs under sheer 
stress, and KEI, a measure of rigidity, represented by the sheer 
stress required to reach half of the RBC maximum elongation. Data 
shown as mean ± 1 standard deviation for the control group (n = 3).
Fig. 2 (A) Morphology index of red blood cells (RBCs) stored for up 
to 14 days post-deglycerolization at 1–6°C. Data shown as mean ± 
1 standard deviation for the control group (n = 3). (B) Microscopic 
images of RBC morphology at 1 and 14 days of hypothermic 
storage post-deglycerolization from thin smear slide preparations. 
The control images are from a representative sample taken from 
preparations of 1 RBC unit from the control group. The control unit 
images contain RBCs undergoing various states of crenation due 
to the hypothermic storage lesion, which should not be confused 
with pathologic acanthocytosis. RBCs from both the control and 
McLeod units will naturally undergo crenation, which may obscure 
or artificially increase the degree of acanthocytosis in the McLeod 
sample.
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Genotyping was also performed on the control units, 
indicating that the method developed to collect and isolate DNA 
was successful in producing samples for RBC genotyping for 
non-leukocyte–reduced cryopreserved RBCs. However, when 
this method was tested on leukocyte-reduced cryopreserved 
RBCs (n = 3), the insufficient or fragmented DNA collected did 
not amplify, so no molecular results were obtained.
Discussion
From this investigation, it is apparent that McLeod RBCs 
can be cryopreserved using a manual glycerolization procedure 
and an automated deglycerolization method with process 
adaptations. Like all “open system” unit modifications, RBCs 
deglycerolized in this manner would have a 24-hour post-
deglycerolization expiration date. Nevertheless, this study 
provides evidence that RBCs of this phenotype can be stored 
for up to 14 days post-thaw and still meet quality standards 
for Hgb, Hct, and hemolysis. This finding suggests that RBCs 
collected from McLeod donors can be cryopreserved using a 
closed-system cell processor and have the benefit of extended 
hypothermic storage using current methods at CBS.
Although quality standards were met in this study, there 
were differences observed between the McLeod RBCs and the 
control units for the additional quality parameters (osmotic 
fragility, MCV, RBC deformability, and morphology). These 
differences are likely attributed to donor factors (McLeod 
phenotype) and not to cell processing and cryopreservation 
methods.14 The most prominent deviation from the control data 
for the McLeod RBC was detected in RBC rigidity. Typically, 
as hypothermically stored RBCs age, their morphology 
demonstrates crenation and eventually becomes more 
spheroid, but their ability to deform remains unaffected.15,16 
The McLeod donor unit demonstrated a substantial increase in 
membrane rigidity post-deglycerolization. Because the control 
units exhibit KEI values lower than typical hypothermically 
stored RBCs at CBS (indicating that their membranes are less 
rigid likely due to the effects of cryopreservation), it can be 
concluded that acanthocytosis typical of McLeod phenotype 
RBCs causes increased RBC membrane rigidity and reduced 
deformability.16 Additionally, it is not surprising that although 
the McLeod RBCs demonstrate decreases in deformability, 
they are still stable during hypothermic storage, which agrees 
with findings previously reported by Ballas et al.,14 in which 
McLeod RBCs demonstrated mechanical stability but reduced 
deformability.
This study was also successful in demonstrating a 
method to obtain genetic material from non-leukocyte–
reduced cryopreserved RBCs for genotyping and molecular 
investigations. Although the method described requires 
further development, it shows proof of concept that genomic 
DNA for molecular analyses on units cryopreserved for 
20 years can be obtained. Having this capability allows 
molecular confirmation of (and potentially further elucidation 
of) the phenotype of previously banked rare units. Further 
improvements of this method are required to reduce the 
potential for bacterial contamination when obtaining samples 
and to develop an alternative method to obtain genetic 
material from leukocyte-reduced units. It is unknown whether 
sufficient DNA can be obtained from leukocyte-reduced units 
if the sample processing volume was increased or whether 
leukocyte reduction itself degrades DNA, making sufficient 
DNA for molecular analyses unattainable.
Finally, it is important to draw attention again to the fact 
that cryopreserved RBCs with exceedingly rare and unusual 
phenotypes can be retained in storage for at least 30 years. 
Management of these units will require a greater understand-
ing of how the quality of these units with rare phenotypes are 
affected by the cryopreservation process and how changes 
in manufacturing will influence these characteristics. Future 
studies should evaluate the quality of cryopreserved RBCs with 
phenotypes with known RBC membrane abnormalities such 
as those found in the MNS (MkMk), Diego (southeast Asian 
ovalocytosis), Gerbich (Yus and Leach), and Gil blood group 
systems. Not only will this information allow us to put these 
components to better use, but it will also allow us to improve 
management policies for this patient population, ensuring that 
adequate components are available for use.
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